Key Takeaways

  • Forxiga is the UK/EU brand for dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor wholly owned by AstraZeneca; the US brand is Farxiga.
  • In the UK it carries three approved indications: type 2 diabetes (adults and children aged 10+), symptomatic chronic heart failure across the ejection-fraction range, and chronic kidney disease in adults.
  • Eligibility is defined by the approved indications and clinician judgement, not by a diagnosis alone; not all patients with diabetes, heart failure or kidney disease qualify.
  • AstraZeneca reported Farxiga/Forxiga revenue of $8,405 million for FY2025 within its Cardiovascular, Renal and Metabolic (CVRM) therapy area, with growth attributed to the heart-failure and CKD indications.
  • Loss of exclusivity is the defining risk: the compound patent has expired and UK SPCs were held invalid on appeal in July 2025, with generics now available across the UK, EU and US.

Introduction

Forxiga is the UK and European brand name for dapagliflozin, an oral medicine developed and now wholly owned by AstraZeneca plc (LSE:AZN); the same molecule is sold in the United States as Farxiga. It belongs to a class known as sodium-glucose co-transporter 2 (SGLT2) inhibitors.

What makes the product notable for investors is how far its role has widened. Originally approved as a type 2 diabetes therapy, dapagliflozin is now indicated in the UK across three distinct areas: insufficiently controlled type 2 diabetes, symptomatic chronic heart failure and chronic kidney disease.

Eligibility for any of these uses is defined by the approved indications and clinician judgement, not by a diagnosis alone. AstraZeneca reported Farxiga/Forxiga revenue of $8,405 million for the 2025 financial year, making it a material contributor to its cardiorenal business, even as newly available generics reshape the outlook.

What is Forxiga?

Forxiga is a film-coated tablet containing dapagliflozin. In the UK the marketing authorisation is held by AstraZeneca UK Limited; the European Union centralised authorisation is held by AstraZeneca AB in Sweden. Both are subsidiaries of AstraZeneca plc, which remains listed on the London Stock Exchange under ticker AZN and sits in the FTSE 100.

The medicine is fully approved and marketed, not investigational. Its UK Summary of Product Characteristics on the electronic medicines compendium was last revised on 24 September 2024 and lists three indications.

Dapagliflozin originated in a former Bristol-Myers Squibb/AstraZeneca diabetes alliance. AstraZeneca acquired full global rights when it bought out BMS's share of that alliance in 2014, so the product is today a direct AstraZeneca asset with no active third-party co-ownership.

It is worth noting that a regulatory substance index or product-file listing only evidences that regulatory files exist. Such an entry is not, in itself, proof of a new approval, a change of ownership, a launch or any commercial success.

How does dapagliflozin work?

Dapagliflozin selectively and reversibly inhibits SGLT2, a transporter in the proximal tubule of the kidney responsible for reabsorbing most of the glucose filtered by the kidneys. By blocking it, the drug reduces glucose reabsorption and increases the amount of glucose excreted in the urine, a process called glucuresis.

According to the approved product information, this mechanism is accompanied by natriuretic (sodium-excreting) and haemodynamic effects. These are understood to underpin the medicine's cardiovascular and renal benefits, which appear to operate independently of its glucose-lowering action.

That decoupling matters commercially. It is the basis on which dapagliflozin moved from being purely a glucose-control agent into a therapy used in patients who may not have diabetes at all, such as some people with heart failure or chronic kidney disease.

As with the wider SGLT2 class, labelling reflects safety considerations that clinicians weigh when prescribing, including diabetic ketoacidosis, genital and urinary tract infections and volume depletion.

Which indications are approved in the UK?

The UK SmPC lists three indications. The first is type 2 diabetes mellitus: dapagliflozin is indicated in adults and children aged 10 years and above for insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise, either as monotherapy or in combination.

The second is symptomatic chronic heart failure in adults. The single label wording covers the full range of left ventricular ejection fraction, meaning both reduced (HFrEF) and preserved (HFpEF) ejection fraction, rather than being split by ejection fraction.

The third is chronic kidney disease in adults. Across all three, it is important to stress that eligibility is determined by the approved indications and a prescriber's clinical judgement. Not every patient with diabetes, heart failure or kidney disease is a candidate.

The EU indications, held by AstraZeneca AB, mirror the UK wording. In the US, Farxiga's indications are framed differently, with heart failure described in terms of reducing the risk of cardiovascular death, hospitalisation and urgent visits; indications should not be merged across the UK, EU and US.

How does Forxiga fit into AstraZeneca's cardiorenal strategy?

AstraZeneca reports dapagliflozin within its Cardiovascular, Renal and Metabolic (CVRM) therapy area. The medicine sits at the centre of a strategy built around treating overlapping cardiac, kidney and metabolic conditions with a single mechanism.

The sequence of milestones illustrates that widening role. Forxiga received its initial EU authorisation for type 2 diabetes on 11 November 2012, and the US followed for diabetes in January 2014. In the US, a heart-failure indication for HFrEF arrived in May 2020, chronic kidney disease in April 2021, and an expansion of heart failure across the full ejection-fraction range in May 2023.

This progression is what turned a diabetes tablet into a cardiorenal franchise. AstraZeneca has attributed recent revenue growth to the heart-failure and CKD indications rather than the original diabetes use.

For the group, dapagliflozin also serves as a strategic anchor for a broader CVRM pipeline and for the company's positioning in chronic diseases that carry large and growing patient populations.

How important is the product commercially?

Commercially, dapagliflozin is one of AstraZeneca's larger single products. The company separately discloses its revenue, and in the FY2025 results announcement Farxiga/Forxiga total revenue was reported at $8,405 million.

That scale means the medicine is a meaningful contributor to CVRM segment sales, which introduces a degree of revenue concentration. A material shift in dapagliflozin's trajectory would be felt at the therapy-area level.

On the addressable market, dapagliflozin targets conditions that are common and, in qualitative terms, expanding as populations age and cardiometabolic disease becomes more prevalent. AstraZeneca does not assert a specific market share here, and no forward revenue figure is claimed.

Where product-level economics such as pricing net of discounts are not separately disclosed, that detail should be treated as not published rather than estimated. The headline revenue figure is the primary company disclosure and the most reliable commercial anchor.

What competitors does it face?

Dapagliflozin competes within a crowded SGLT2-inhibitor class. Its closest cardiorenal rival is empagliflozin (Jardiance), marketed by Boehringer Ingelheim and Eli Lilly, which addresses overlapping heart-failure and kidney indications.

Other branded SGLT2 inhibitors include canagliflozin (Invokana) from Johnson & Johnson's Janssen, ertugliflozin (Steglatro) from Merck/MSD, sotagliflozin (Inpefa/Zynquista) from Lexicon Pharmaceuticals and bexagliflozin (Brenzavvy) from TheracosBio.

The most significant competitive development, however, is the arrival of generic dapagliflozin itself. Multiple manufacturers, including names such as Teva, Glenmark, Sandoz, Cipla, Lupin and Aurobindo, have entered following the loss of patent protection.

Generic versions of the same molecule can exert pricing and volume pressure on the branded product, and low-cost entrants may influence reimbursement decisions by bodies such as NICE and the NHS, as well as US payers.

What are the growth drivers and the principal risks?

On the positive side, the breadth of approved indications is a structural driver: growth has been linked to the heart-failure and CKD uses, which reach patient groups beyond diabetes. Broadening clinical adoption of SGLT2 inhibitors in cardiorenal care may support demand for the class overall.

The dominant risk is loss of exclusivity. The dapagliflozin compound patent expired in the UK and EU on 15 May 2023. In the UK, the High Court revoked AstraZeneca's dapagliflozin SPC and patent in April 2025, and on 16 July 2025 the Court of Appeal ([2025] EWCA Civ 903) upheld the invalidity, clearing generic entry. In the US the base compound patent lapsed around 4 April 2026, with multiple generics approved from April 2026.

AstraZeneca retains later method-of-use patents tied to the heart-failure and CKD indications, with expiries reported into 2039-2041, but these remain subject to litigation risk and do not restore compound-level protection.

Further risks include class-wide SGLT2 safety considerations affecting labelling and uptake, direct competition from empagliflozin, and pricing and reimbursement pressure as generics spread. Given the product's contribution to CVRM sales, revenue concentration compounds these factors.

What should investors monitor?

Investors may monitor the pace of generic erosion across the UK, EU and US, since this is the single largest variable for the franchise. The gap between branded and generic pricing, and how quickly volumes shift, will shape the revenue path.

The status of remaining method-of-use patents and any related litigation is another area to watch, as it governs how much of the heart-failure and CKD franchise AstraZeneca can defend.

Reimbursement decisions from NICE, the NHS and US payers are relevant, particularly where low-cost generics change cost-effectiveness assessments. Company disclosures in future results announcements will show how dapagliflozin revenue and its CVRM contribution evolve.

None of the above is a recommendation to buy, sell or hold, and nothing here is medical advice. Prescribing decisions rest with clinicians and the approved product information. Investors should form their own view and consider professional advice where appropriate.